<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358253</url>
  </required_header>
  <id_info>
    <org_study_id>RJ-2010-56</org_study_id>
    <nct_id>NCT01358253</nct_id>
  </id_info>
  <brief_title>Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and efficacy of Rituximab combined
      with chemotherapy in CD20+ adult acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute lymphoblastic leukemia (ALL) is a group of biologically heterogeneous diseases with
      diverse prognosis. Novel strategies for adult ALL have approached a CR rate of over 80%,
      which is similar to pediatric ALL. But the long term survival of adult ALL is only 30%-40%,
      much lower than pediatric patients.

      In our trial, all the patients will first receive Vincristine 1.4mg/m2, max 2mg IV days
      1,8,15,22, Daunorubicin 45mg/m2 IV days 1-3,Cyclophosphamide 750mg/m2 IV day 1 and prednisone
      40-60mg/m2,by mouth days 1-14 (VDCP)regimen as initial induction therapy. If patients achieve
      complete remission after induction, they will be enrolled in our study for further
      consolidation and maintenance. If the tumor cells in bone marrow remain 5% to 20% after
      induction, the patients will receive VDCLP(VDCP+L-asparaginase 6000IU/m2 IV days5,7,9,11,13)
      and be enrolled until complete remission.

      Rituximab is the main experimental intervention in our study.The consolidation regimen is
      HyperCVAD/MA or R-HyperCVAD/MA for totally 8 courses. The maintenance regimen includes
      6-Mercaptopurine+Methotrexate for 24 months, Vincristine+Prednisone for the first 12 months,
      L-asparaginase in month 3 and 9 with or without Rituximab in month 6 and 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR duration</measure>
    <time_frame>After two 21-day courses</time_frame>
    <description>Bone marrow MRD examination every two months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>HyperCVAD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consolidation:
HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.
Maintenance:
6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-HyperCVAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consolidation:
R-HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.
Maintenance:
6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9. Rituximab in month 6 and 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).</description>
    <arm_group_label>HyperCVAD</arm_group_label>
    <arm_group_label>R-HyperCVAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).</description>
    <arm_group_label>HyperCVAD</arm_group_label>
    <arm_group_label>R-HyperCVAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.</description>
    <arm_group_label>HyperCVAD</arm_group_label>
    <arm_group_label>R-HyperCVAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)</description>
    <arm_group_label>HyperCVAD</arm_group_label>
    <arm_group_label>R-HyperCVAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).</description>
    <arm_group_label>HyperCVAD</arm_group_label>
    <arm_group_label>R-HyperCVAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.</description>
    <arm_group_label>HyperCVAD</arm_group_label>
    <arm_group_label>R-HyperCVAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).
Maintenance:375 mg/m2 IV in 6th month and 12th month.</description>
    <arm_group_label>R-HyperCVAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-Mercaptopurine</intervention_name>
    <description>Maintenance:60mg/m2 daily for 24 months.</description>
    <arm_group_label>HyperCVAD</arm_group_label>
    <arm_group_label>R-HyperCVAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.</description>
    <arm_group_label>HyperCVAD</arm_group_label>
    <arm_group_label>R-HyperCVAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-asparaginase</intervention_name>
    <description>Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.</description>
    <arm_group_label>HyperCVAD</arm_group_label>
    <arm_group_label>R-HyperCVAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CD20-positive ALL

          -  Adequate liver function (bilirubin less than or equal to 1.5*ULN, unless considered
             due to tumor), and renal function (creatinine less than or equal to 1.5*ULN, unless
             considered due to tumor)

          -  Signed informed consent

        Exclusion Criteria:

          -  Prior history of treatment with high-dose Ara-C, MTX or rituximab

          -  Pregnant or lactating women

          -  History of allergy to rituximab

          -  Unable to sign informed consent

          -  Active replication of HBV

          -  History of stem cell transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weili Zhao, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of hematology Ruijin Hospital/Shanghai Institute of Hematology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <name_title>Zhao Weili/Professor</name_title>
    <organization>Department of hematology Ruijin Hospital/Shanghai Institute of hematology</organization>
  </responsible_party>
  <keyword>Rituximab</keyword>
  <keyword>HyperCVAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

